There’s a quiet revolution brewing in biotech, and it’s happening in Phoenixville, PA, of all places. PleoPharma, Inc. just dropped a $36M Series B to push its lead candidate, PP-01, into Phase 3. The company isn’t chasing headlines, it’s chasing something bigger: the first FDA Fast Track-designated therapy for Cannabis Withdrawal Syndrome. That’s not a hype line; that’s a clinical-stage breakthrough for a problem 20M Americans are wrestling with and the FDA still hasn’t approved a single drug to treat.
Founded in 2019 by Dr. Ginger Constantine and Dr. Jay Constantine, the duo built PleoPharma on what they saw firsthand in patients, real withdrawal, real suffering, zero options. Instead of shrugging, they engineered a therapy that actually speaks the body’s language. PP-01 is an oral, once-daily small molecule that targets CB1 receptors while regulating mesolimbic neurotransmitters, the brain’s switchboard for craving and calm. In Phase 2b, it hit its primary endpoint with statistical significance (p = 0.02) and showed strong tolerability, proving the concept isn’t just smoke and mirrors.
The Series B, led by biotech-specialist funds with a generalist investor jumping in, brings PleoPharma’s total raise to $53.5 M. SuperVision Partners LLC and Castle Hill Capital Partners Inc. ran placement. What’s next? Phase 3, a national rollout across 22 addiction centers, and a team expansion that looks more like scaling a rocket than staffing a lab. Dr. Ginger Constantine leads as CEO and Chair, Dr. Jay Constantine serves as CMO and Director, with Daniel A. Cartwright (CFO) and Thomas Poché, J.D., Ph.D. (General Counsel & Head of IP) tightening the bolts. Add veterans like Adeyinka Abinusawa (Chief CMC Officer), Dawn Halkuff (IR), Kristine Craig (QA), Robert Finizio (Exec Director), Ashley Slagle, Ph.D. (Clinical Outcome), Lois Rosenberger, Ph.D. (Regulatory), Shelli Graham, Ph.D. (Med/Clinical Research), Bharat Warrier (CMC), and Robert Lahman (Managed Care), this is a lineup that knows how to get drugs approved and keep regulators nodding.
The science is strong, but the strategy’s stronger. PP-01 sits on global patent protection through 2041, is built under GMP standards, and is already Fast Track-tagged. The goal: complete Phase 3 by late 2026, file an NDA, and finally give clinicians a tool for Cannabis Use Disorder that isn’t another patch-up job. The market’s wide open, the need’s massive, and the timing couldn’t be sharper.
PleoPharma isn’t just treating withdrawal, it’s treating a blind spot in modern medicine. The Constantine team took a condition people laugh off and gave it scientific gravity. That’s not just biotech innovation, it’s cultural correction. This isn’t about getting high. It’s about helping millions come down safe.
